

UNITED STATES DISTRICT COURT
FOR THE CENTRAL DISTRICT OF CALIFORNIA

October 2025 Grand Jury

UNITED STATES OF AMERICA,

Plaintiff,

v.

WISAM KHADER,
JUSTIN EVANS, and
PATRICK MURPHY,

Defendants.

CR 2:26-cr-00400-AB

I N D I C T M E N T

[21 U.S.C. § 846: Conspiracy to
Distribute and Possess with Intent
to Distribute Controlled
Substances; 21 U.S.C. § 853:
Criminal Forfeiture]

The Grand Jury charges:

[21 U.S.C. § 846]

[ALL DEFENDANTS]

A. INTRODUCTORY ALLEGATIONS

At times relevant to this Indictment:

1. Defendants WISAM KHADER, JUSTIN EVANS, and PATRICK MURPHY were each medical doctors licensed to practice in the State of California and authorized by the United States Drug Enforcement Administration ("DEA") to prescribe controlled substances, including, but not limited to, oxycodone, "amphetamine aspartate amphetamine sulfate", morphine sulphate, diazepam, pregabalin, and buprenorphine.

1 2. Defendants KHADER, EVANS, and MURPHY each practiced
2 medicine within the Central District of California.

3 B. OBJECTS OF THE CONSPIRACY

4 3. Beginning on a date unknown to the Grand Jury, but no later
5 than in or about October 2019, and continuing to an unknown date, but
6 no earlier than in or about March 2024, in Los Angeles and Orange
7 Counties, within the Central District of California, and elsewhere,
8 defendants WISAM KHADER, JUSTIN EVANS, and PATRICK MURPHY, together
9 with others known and unknown to the Grand Jury, conspired to
10 knowingly and intentionally distribute, and possess with intent to
11 distribute, the following controlled substances:

12 a. Amphetamine, a Schedule II controlled substance, in
13 violation of Title 21, United States Code, Section 841(a), (b)(1)(C);

14 b. Buprenorphine, a Schedule III narcotic drug controlled
15 substance, in violation of Title 21, United States Code, Section
16 841(a), (b)(1)(E);

17 c. Diazepam, a Schedule IV controlled substance, in
18 violation of Title 21, United States Code, Section 841(a), (b)(2);

19 d. Morphine, a Schedule II narcotic drug controlled
20 substance, in violation of Title 21, United States Code, Section
21 841(a), (b)(1)(C);

22 e. Oxycodone, a Schedule II narcotic drug controlled
23 substance, in violation of Title 21, United States Code, Section
24 841(a), (b)(1)(C); and

25 f. Pregabalin, a Schedule V controlled substance, in
26 violation of Title 21, United States Code, Section 841(a), (b)(3).

1 C. MEANS BY WHICH THE OBJECTS OF THE CONSPIRACY WERE TO BE
2 ACCOMPLISHED

3 4. The objects of the conspiracy were to be accomplished, in
4 substance, as follows:

5 a. Defendants KHADER, EVANS, and MURPHY, while acting and
6 intending to act outside the usual course of professional practice
7 and without a legitimate medical purpose, issued prescriptions for
8 drugs containing federally controlled substances, including
9 amphetamine, buprenorphine, diazepam, morphine, oxycodone, and
10 pregabalin, among others, to one another.

11 b. Defendants KHADER, EVANS, and MURPHY prescribed these
12 medications after performing inadequate medical examinations, outside
13 the usual course of professional practice, on the individual to whom
14 the controlled substance was prescribed.

15 c. Defendant EVANS provided blank prescriptions to
16 defendant KHADER so that defendant KHADER could issue prescriptions
17 to himself under defendant EVANS's prescribing authority.

18 d. Defendants EVANS and MURPHY would prescribe controlled
19 substances to one another in exchange for favors, including covering
20 each other's work shifts, knowing that they were acting outside the
21 usual course of professional practice and without a legitimate
22 medical purpose.

23 e. Defendants KHADER, EVANS, and MURPHY, and others known
24 and unknown to the Grand Jury, would use the prescriptions to obtain
25 controlled substances from pharmacies throughout the Central District
26 of California, and elsewhere.

1 D. OVERT ACTS

2 On or about the following dates, in furtherance of the
3 conspiracy and to accomplish its objects, defendants KHADER, EVANS,
4 and MURPHY, and others known and unknown to the Grand Jury, committed
5 various overt acts in Los Angeles and Orange Counties, within the
6 Central District of California, and elsewhere, including, but not
7 limited to, the following:

8 Overt Act No. 1: On December 14, 2019, defendant EVANS issued
9 a prescription for "amphetamine aspartate amphetamine sulfate" 20 mg
10 tablets, which contained a Schedule II controlled substance, to
11 defendant KHADER.

12 Overt Act No. 2: On January 1, 2020, defendant KHADER issued
13 a prescription for buprenorphine hydrochloride 8 mg tablets, which
14 contained a Schedule III narcotic drug controlled substance, to
15 defendant MURPHY.

16 Overt Act No. 3: On January 30, 2020, in text messages,
17 defendant EVANS texted defendant MURPHY that he had his prescription
18 pads on him if defendant MURPHY "need[s] anything."

19 Overt Act No. 4: On January 30, 2020, in text messages,
20 defendant EVANS attempted to convince defendant MURPHY to cover a
21 hospital clinic shift by promising to pay defendant MURPHY \$2,000 and
22 to fill Adderall prescriptions (a brand name for a prescription drug
23 containing amphetamine, a Schedule II controlled substance) for
24 defendant MURPHY. Defendant EVANS encouraged MURPHY to "take some
25 addy" and cover the shift.

26 Overt Act No. 5: On February 2, 2020, in a text message,
27 defendant EVANS told defendant MURPHY, "And I was risking my license
28

1 writing scripts for all your buddies and got in trouble twice for
2 doing that."

3 Overt Act No. 6: On February 24, 2020, defendant EVANS gave
4 defendants MURPHY and KHADER permission to take his blank
5 prescription pad from his backpack and write themselves prescriptions
6 in EVANS's name.

7 Overt Act No. 7: On February 26, 2020, defendant EVANS issued
8 a prescription for oxycodone hydrochloride acetaminophen 10-325 mg
9 tablets, which contained a Schedule II narcotic drug controlled
10 substance, to defendant KHADER.

11 Overt Act No. 8: On February 26, 2020, defendant EVANS issued
12 a prescription for "amphetamine aspartate amphetamine sulfate" 20 mg
13 tablets, which contained a Schedule II controlled substance, to
14 defendant KHADER.

15 Overt Act No. 9: On April 5, 2020, defendant EVANS issued a
16 prescription for oxycodone hydrochloride acetaminophen 10-325 mg
17 tablets, which contained a Schedule II narcotic drug controlled
18 substance, to defendant KHADER.

19 Overt Act No. 10: On April 7, 2020, defendant EVANS issued a
20 prescription for "amphetamine aspartate amphetamine sulfate" 20 mg
21 tablets, which contained a Schedule II controlled substance, to
22 defendant KHADER. Defendant KHADER filled the prescription on or
23 about the same date.

24 Overt Act No. 11: On April 12, 2020, defendant KHADER issued a
25 prescription for oxycodone hydrochloride acetaminophen 10-325 mg
26 tablets, which contained a Schedule II narcotic drug controlled
27 substance, to defendant MURPHY.

1 Overt Act No. 12: On April 28, 2020, defendant KHADER issued a
2 prescription for oxycodone hydrochloride 30 mg tablets, which
3 contained a Schedule II narcotic drug controlled substance, to
4 defendant MURPHY.

5 Overt Act No. 13: On May 5, 2020, defendant KHADER issued a
6 prescription for "amphetamine aspartate amphetamine sulfate" 20 mg
7 tablets, which contained a Schedule II controlled substance, to
8 defendant EVANS.

9 Overt Act No. 14: On May 6, 2020, defendant EVANS issued a
10 prescription for oxycodone hydrochloride 30 mg tablets, which
11 contained a Schedule II narcotic drug controlled substance, to
12 defendant KHADER.

13 Overt Act No. 15: On May 27, 2020, defendant KHADER issued a
14 prescription for oxycodone hydrochloride 30 mg tablets, which
15 contained a Schedule II narcotic drug controlled substance, to
16 defendant MURPHY.

17 Overt Act No. 16: On July 22, 2020, defendant KHADER issued a
18 prescription for "amphetamine aspartate amphetamine sulfate" 20 mg
19 tablets, which contained a Schedule II controlled substance, to
20 defendant EVANS.

21 Overt Act No. 17: On August 18, 2020, defendant KHADER issued
22 a prescription for oxycodone hydrochloride 20 mg tablets, which
23 contained a Schedule II narcotic drug controlled substance, to
24 defendant MURPHY.

25 Overt Act No. 18: On August 28, 2020, defendant EVANS issued a
26 prescription for "amphetamine aspartate amphetamine sulfate" 20 mg
27 tablets, which contained a Schedule II controlled substance, to
28 defendant KHADER.

1 Overt Act No. 19: On September 19, 2020, defendant KHADER
2 issued a prescription for oxycodone hydrochloride 20 mg tablets,
3 which contained a Schedule II narcotic drug controlled substance, to
4 defendant MURPHY.

5 Overt Act No. 20: On October 28, 2020, defendant KHADER issued
6 a prescription for oxycodone hydrochloride 20 mg tablets, which
7 contained a Schedule II narcotic drug controlled substance, to
8 defendant MURPHY.

9 Overt Act No. 21: On November 9, 2020, defendant KHADER issued
10 a prescription for oxycodone hydrochloride 20 mg tablets, which
11 contained a Schedule II narcotic drug controlled substance, to
12 defendant MURPHY.

13 Overt Act No. 22: On November 27, 2020, defendant KHADER
14 issued a prescription for "amphetamine aspartate amphetamine sulfate"
15 20 mg tablets, which contained a Schedule II controlled substance, to
16 defendant EVANS.

17 Overt Act No. 23: On December 6, 2020, defendant EVANS issued
18 a prescription for "amphetamine aspartate amphetamine sulfate" 20 mg
19 tablets, which contained a Schedule II controlled substance, to
20 defendant KHADER.

21 Overt Act No. 24: On December 28, 2020, defendant EVANS issued
22 a prescription for diazepam 5 mg tablets, which contained a Schedule
23 IV controlled substance, to defendant KHADER.

24 Overt Act No. 25: On January 9, 2021, defendant MURPHY issued
25 a prescription for pregabalin 100 mg capsules, which contained a
26 Schedule V controlled substance, to defendant KHADER.

1 Overt Act No. 26: On January 28, 2021, defendant EVANS issued
2 a prescription for diazepam 5 mg tablets, which contained a Schedule
3 IV controlled substance, to defendant KHADER.

4 Overt Act No. 27: On February 8, 2021, defendant KHADER issued
5 a prescription for oxycodone hydrochloride 20 mg tablets, which
6 contained a Schedule II narcotic drug controlled substance, to
7 defendant MURPHY.

8 Overt Act No. 28: On February 25, 2021, defendant MURPHY
9 issued a prescription for pregabalin 100 mg capsules, which contained
10 a Schedule V controlled substance, to defendant KHADER.

11 Overt Act No. 29: On March 13, 2021, defendant KHADER issued a
12 prescription for morphine sulphate 30 mg tablets, which contained a
13 Schedule II narcotic drug controlled substance, to defendant MURPHY.

14 Overt Act No. 30: On March 31, 2021, defendant EVANS issued a
15 prescription for diazepam 5 mg tablets, which contained a Schedule IV
16 controlled substance, to defendant KHADER.

17 Overt Act No. 31: On April 13, 2021, defendant KHADER issued a
18 prescription for diazepam 5mg tablets, which contained a Schedule IV
19 controlled substance, to defendant MURPHY.

20 Overt Act No. 32: On April 29, 2021, defendant EVANS issued a
21 prescription for diazepam 5 mg tablets, which contained a Schedule IV
22 controlled substance, to defendant KHADER.

23 Overt Act No. 33: On May 11, 2021, defendant KHADER issued a
24 prescription for "amphetamine aspartate amphetamine sulfate" 20 mg
25 tablets, which contained a Schedule II controlled substance, to
26 defendant EVANS.

1 Overt Act No. 34: On May 12, 2021, defendant KHADER issued a
2 prescription for diazepam 5mg tablets, which contained a Schedule IV
3 controlled substance, to defendant MURPHY.

4 Overt Act No. 35: On May 22, 2021, defendant EVANS issued a
5 prescription for "amphetamine aspartate amphetamine sulfate" 20 mg
6 tablets, which contained a Schedule II controlled substance, to
7 defendant KHADER.

8 Overt Act No. 36: On June 2, 2021, defendant KHADER issued a
9 prescription for oxycodone hydrochloride 20 mg tablets, which
10 contained a Schedule II narcotic drug controlled substance, to
11 defendant MURPHY.

12 Overt Act No. 37: On July 6, 2021, defendant KHADER issued a
13 prescription for oxycodone hydrochloride 20 mg tablets, which
14 contained a Schedule II narcotic drug controlled substance, to
15 defendant MURPHY.

16 Overt Act No. 38: On August 9, 2021, defendant KHADER issued a
17 prescription for oxycodone hydrochloride 20 mg tablets, which
18 contained a Schedule II narcotic drug controlled substance, to
19 defendant MURPHY.

20 Overt Act No. 39: On August 18, 2021, defendant KHADER issued
21 a prescription for "amphetamine aspartate amphetamine sulfate" 20 mg
22 tablets, which contained a Schedule II controlled substance, to
23 defendant EVANS.

24 Overt Act No. 40: On September 9, 2021, defendant KHADER
25 issued a prescription for oxycodone hydrochloride 20 mg tablets,
26 which contained a Schedule II narcotic drug controlled substance, to
27 defendant MURPHY.

1 Overt Act No. 41: On September 12, 2021, defendant EVANS
2 issued a prescription for "amphetamine aspartate amphetamine sulfate"
3 20 mg tablets, which contained a Schedule II controlled substance, to
4 defendant KHADER.

5 Overt Act No. 42: On October 9, 2021, defendant KHADER issued
6 a prescription for oxycodone hydrochloride 20 mg tablets, which
7 contained a Schedule II narcotic drug controlled substance, to
8 defendant MURPHY.

9 Overt Act No. 43: On October 15, 2021, defendant KHADER issued
10 a prescription for "amphetamine aspartate amphetamine sulfate" 20 mg
11 tablets, which contained a Schedule II controlled substance, to
12 defendant EVANS.

13 Overt Act No. 44: On November 9, 2021, defendant KHADER issued
14 a prescription for oxycodone hydrochloride 20 mg tablets, which
15 contained a Schedule II narcotic drug controlled substance, to
16 defendant MURPHY.

17 Overt Act No. 45: On December 11, 2021, defendant EVANS issued
18 a prescription for "amphetamine aspartate amphetamine sulfate" 20 mg
19 tablets, which contained a Schedule II controlled substance, to
20 defendant KHADER.

21 Overt Act No. 46: On December 15, 2021, defendant KHADER
22 issued a prescription for oxycodone hydrochloride 20 mg tablets,
23 which contained a Schedule II narcotic drug controlled substance, to
24 defendant MURPHY.

25 Overt Act No. 47: On January 3, 2022, defendant MURPHY issued
26 a prescription for pregabalin 100 mg capsules, which contained a
27 Schedule V controlled substance, to defendant KHADER.

1 Overt Act No. 48: On January 27, 2022, defendant KHADER issued
2 a prescription for oxycodone hydrochloride 20 mg tablets, which
3 contained a Schedule II narcotic drug controlled substance, to
4 defendant MURPHY.

5 Overt Act No. 49: On January 31, 2022, defendant MURPHY issued
6 a prescription for pregabalin 100 mg capsules, which contained a
7 Schedule V controlled substance, to defendant KHADER.

8 Overt Act No. 50: On February 28, 2022, defendant MURPHY
9 issued a prescription for pregabalin 100 mg capsules, which contained
10 a Schedule V controlled substance, to defendant KHADER.

11 Overt Act No. 51: On March 1, 2022, defendant KHADER issued a
12 prescription for oxycodone hydrochloride 20 mg tablets, which
13 contained a Schedule II narcotic drug controlled substance, to
14 defendant MURPHY.

15 Overt Act No. 52: On March 29, 2022, defendant KHADER issued a
16 prescription for oxycodone hydrochloride 20 mg tablets, which
17 contained a Schedule II narcotic drug controlled substance, to
18 defendant MURPHY.

19 Overt Act No. 53: On March 30, 2022, defendant MURPHY issued a
20 prescription for pregabalin 100 mg capsules, which contained a
21 Schedule V controlled substance, to defendant KHADER.

22 Overt Act No. 54: On April 27, 2022, defendant MURPHY issued a
23 prescription for pregabalin 100 mg capsules, which contained a
24 Schedule V controlled substance, to defendant KHADER.

25 Overt Act No. 55: On May 3, 2022, defendant KHADER issued a
26 prescription for oxycodone hydrochloride 20 mg tablets, which
27 contained a Schedule II narcotic drug controlled substance, to
28 defendant MURPHY.

1 Overt Act No. 56: On May 25, 2022, defendant MURPHY issued a
2 prescription for pregabalin 100 mg capsules, which contained a
3 Schedule V controlled substance, to defendant KHADER.

4 Overt Act No. 57: On June 3, 2022, defendant KHADER issued a
5 prescription for oxycodone hydrochloride 20 mg tablets, which
6 contained a Schedule II narcotic drug controlled substance, to
7 defendant MURPHY.

8 Overt Act No. 58: On July 1, 2022, defendant KHADER issued a
9 prescription for oxycodone hydrochloride 20 mg tablets, which
10 contained a Schedule II narcotic drug controlled substance, to
11 defendant MURPHY.

12 Overt Act No. 59: On September 6, 2022, defendant KHADER
13 issued a prescription for oxycodone hydrochloride 20 mg tablets,
14 which contained a Schedule II narcotic drug controlled substance, to
15 defendant MURPHY.

16 Overt Act No. 60: On October 4, 2022, defendant KHADER issued
17 a prescription for oxycodone hydrochloride 20 mg tablets, which
18 contained a Schedule II narcotic drug controlled substance, to
19 defendant MURPHY.

20 Overt Act No. 61: On November 1, 2022, defendant KHADER issued
21 a prescription for oxycodone hydrochloride 20 mg tablets, which
22 contained a Schedule II narcotic drug controlled substance, to
23 defendant MURPHY.

24 Overt Act No. 62: On December 1, 2022, defendant KHADER issued
25 a prescription for oxycodone hydrochloride 20 mg tablets, which
26 contained a Schedule II narcotic drug controlled substance, to
27 defendant MURPHY.

1 Overt Act No. 63: On January 4, 2023, defendant KHADER issued
2 a prescription for oxycodone hydrochloride 20 mg tablets, which
3 contained a Schedule II narcotic drug controlled substance, to
4 defendant MURPHY.

5 Overt Act No. 64: On April 4, 2023, defendant KHADER issued a
6 prescription for oxycodone hydrochloride 20 mg tablets, which
7 contained a Schedule II narcotic drug controlled substance, to
8 defendant MURPHY.

9 Overt Act No. 65: On May 4, 2023, defendant KHADER issued a
10 prescription for oxycodone hydrochloride 20 mg tablets, which
11 contained a Schedule II narcotic drug controlled substance, to
12 defendant MURPHY.

13 Overt Act No. 66: On June 3, 2022, defendant KHADER issued a
14 prescription for pregabalin 100 mg capsules, which contained a
15 Schedule V controlled substance, to defendant MURPHY.

16 Overt Act No. 67: On June 6, 2023, defendant KHADER issued a
17 prescription for oxycodone hydrochloride 20 mg tablets, which
18 contained a Schedule II narcotic drug controlled substance, to
19 defendant MURPHY.

20 Overt Act No. 68: On July 5, 2022, defendant KHADER issued a
21 prescription for pregabalin 100 mg capsules, which contained a
22 Schedule V controlled substance, to defendant MURPHY.

23 Overt Act No. 69: On August 26, 2022, defendant MURPHY issued
24 a prescription for pregabalin 300 mg capsules, which contained a
25 Schedule V controlled substance, to defendant KHADER.

26 Overt Act No. 70: On September 6, 2022, defendant KHADER
27 issued a prescription for pregabalin 100 mg capsules, which contained
28 a Schedule V controlled substance, to defendant MURPHY.

1 Overt Act No. 71: On September 24, 2022, defendant MURPHY
2 issued a prescription for pregabalin 300 mg capsules, which contained
3 a Schedule V controlled substance, to defendant KHADER.

4 Overt Act No. 72: On October 4, 2022, defendant KHADER issued
5 a prescription for pregabalin 100 mg capsules, which contained a
6 Schedule V controlled substance, to defendant MURPHY.

7 Overt Act No. 73: On October 25, 2022, defendant MURPHY issued
8 a prescription for pregabalin 300 mg capsules, which contained a
9 Schedule V controlled substance, to defendant KHADER.

10 Overt Act No. 74: On November 1, 2022, defendant KHADER issued
11 a prescription for pregabalin 100 mg capsules, which contained a
12 Schedule V controlled substance, to defendant MURPHY.

13 Overt Act No. 75: On December 1, 2022, defendant KHADER issued
14 a prescription for pregabalin 100 mg capsules, which contained a
15 Schedule V controlled substance, to defendant MURPHY.

16 Overt Act No. 76: On December 10, 2022, defendant MURPHY
17 issued a prescription for pregabalin 300 mg capsules, which contained
18 a Schedule V controlled substance, to defendant KHADER.

19 Overt Act No. 77: On January 4, 2023, defendant KHADER issued
20 a prescription for pregabalin 100 mg capsules, which contained a
21 Schedule V controlled substance, to defendant MURPHY.

22 Overt Act No. 78: On January 14, 2023, defendant MURPHY issued
23 a prescription for pregabalin 300 mg capsules, which contained a
24 Schedule V controlled substance, to defendant KHADER.

25 Overt Act No. 79: On February 16, 2023, defendant MURPHY
26 issued a prescription for pregabalin 300 mg capsules, which contained
27 a Schedule V controlled substance, to defendant KHADER.

1 Overt Act No. 80: On March 3, 2023, defendant KHADER issued a
2 prescription for pregabalin 100 mg capsules, which contained a
3 Schedule V controlled substance, to defendant MURPHY.

4 Overt Act No. 81: On March 16, 2023, defendant MURPHY issued a
5 prescription for pregabalin 300 mg capsules, which contained a
6 Schedule V controlled substance, to defendant KHADER.

7 Overt Act No. 82: On April 3, 2023, defendant KHADER issued a
8 prescription for pregabalin 100 mg capsules, which contained a
9 Schedule V controlled substance, to defendant MURPHY.

10 Overt Act No. 83: On April 16, 2023, defendant MURPHY issued a
11 prescription for pregabalin 300 mg capsules, which contained a
12 Schedule V controlled substance, to defendant KHADER.

13 Overt Act No. 84: On May 4, 2023, defendant KHADER issued a
14 prescription for pregabalin 100 mg capsules, which contained a
15 Schedule V controlled substance, to defendant MURPHY.

16 Overt Act No. 85: On May 24, 2023, defendant MURPHY issued a
17 prescription for pregabalin 300 mg capsules, which contained a
18 Schedule V controlled substance, to defendant KHADER.

19 Overt Act No. 86: On June 6, 2023, defendant KHADER issued a
20 prescription for pregabalin 100 mg capsules, which contained a
21 Schedule V controlled substance, to defendant MURPHY.

22 Overt Act No. 87: On July 5, 2023, defendant MURPHY issued a
23 prescription for pregabalin 300 mg capsules, which contained a
24 Schedule V controlled substance, to defendant KHADER.

25 Overt Act No. 88: On August 6, 2023, defendant MURPHY issued a
26 prescription for pregabalin 300 mg capsules, which contained a
27 Schedule V controlled substance, to defendant KHADER.

1 Overt Act No. 89: On September 22, 2023, defendant MURPHY
2 issued a prescription for pregabalin 300 mg capsules, which contained
3 a Schedule V controlled substance, to defendant KHADER.

4 Overt Act No. 90: On October 25, 2023, defendant MURPHY issued
5 a prescription for pregabalin 300 mg capsules, which contained a
6 Schedule V controlled substance, to defendant KHADER.

7 Overt Act No. 91: On November 30, 2023, defendant MURPHY
8 issued a prescription for pregabalin 300 mg capsules, which contained
9 a Schedule V controlled substance, to defendant KHADER.

10 Overt Act No. 92: On January 2, 2024, defendant MURPHY issued
11 a prescription for pregabalin 300 mg capsules, which contained a
12 Schedule V controlled substance, to defendant KHADER.

13 Overt Act No. 93: On February 14, 2024, defendant MURPHY
14 issued a prescription for pregabalin 300 mg capsules, which contained
15 a Schedule V controlled substance, to defendant KHADER.

16 Overt Act No. 94: On March 22, 2024, defendant MURPHY issued a
17 prescription for pregabalin 300 mg capsules, which contained a
18 Schedule V controlled substance, to defendant KHADER.

19 Overt Act No. 95: On June 1, 2024, in text messages, defendant
20 MURPHY, in a conversation about avoiding police officers while
21 carrying prescription medications, messaged defendant KHADER that he
22 was "nervous" because "they can legally search the car," and "I think
23 safest play would be to just say it's my prescription cause I do
24 technically have one."

25 Overt Acts No. 96 to 186: Each recipient of a prescription
26 described above in this Indictment filled the prescription.

1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
6
7
8

2

3
4
5
6
7

8
9

10
11
12
13

14
15
16
17

18
19
20

21
22
23
24
25
26
27

1 in value; or (e) has been commingled with other property that cannot
2 be divided without difficulty.

3
4 A TRUE BILL

5
6 /s/
7 Foreperson

8 TODD BLANCHE
9 Acting Attorney General

10 BILAL A. ESSAYLI
11 First Assistant United States
12 Attorney

13 JENNIFER L. WAIER
14 Chief Assistant United States Attorney
15 Chief, Criminal Division

16 
17 FRANCES S. LEWIS
18 Assistant United States Attorney
19 Chief, General Crimes Section

20 KYLE W. KAHAN
21 Assistant United States Attorney
22 Deputy Chief, General Crimes Section

23 RAHUL R.A. HARI
24 Assistant United States Attorney
25 Major Crimes Section
26
27
28